[PDF] Top 20 Guía Para Elaborar Planes de Respuesta a Emergencias

... the long-term is the development of atrophic macular ...the degeneration associated with AMD, or secondary to the presence and regression of the ...its long-term suppression ... See full document

... routine clinic appointment, the patients underwent visual acuity tests, a macular scan using optical coherence tomography, slit-lamp biomicroscopy, and were then injected with ranibizumab if deemed ...The ... See full document

... Factors related to poor follow-up adherence have been identi fi ed in previous studies and include among others older age, greater dis- tance to hospital, and lower baseline ...the long-term is ... See full document

... the long-term clinical outcomes for patients with neovascular age- related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) ... See full document

... and Bevacizumab have been in use for nAMD for some time, with Aflibercept being introduced later [5, ...of treatment to Aflibercept was attempted in patients who were either unresponsive or partly ... See full document

... eovascular Age-Related Macular Degeneration (AMD) Treated with intraOcular Ranibizumab [PrONTO] ” trial explored an alternate dos- ing strategy of intravitreal ranibizumab for all types of ... See full document

... complications related to injection procedure (eg, retinal detachment, endophthalmitis, lens iatrogenic injury, ...in real life it has been shown that a shorter- interval re-treatment is ... See full document

... ideal treatment for this sight-threatening condition would maintain or improve a patient’s vision, whilst limiting the number of treatment ...of treatment imposes a considerable burden for affected ... See full document

... The visual acuity and the safety results were not as good as those seen in patients with predominantly classic CNV treated with ranibizumab alone in the ANCHOR trial. Moreover, 12% of patients treated with combination ... See full document

... FDA-approved treatment for neovascular age-related macular degeneration (AMD); however this treatment modality seems to stabilize, rather than improve vision ...for ... See full document

... of bevacizumab (Avastin ® , Genentech, South San Francisco, CA, USA) is given intravitreally in the superolateral quadrant or inferotemporal quadrant, 3mm, ... See full document

... of macular thickness, assessed by OCT examination, occurred in all the patients and remained stable over the entire follow-up ...in macular thickness was about ... See full document

... additional treatment could have direct implications for final visual acuity, and we should have standardized the period of time for treatment and therapeutic procedures in the two ...additional ... See full document

... during long-term follow-up with retreatment using a pro re nata regimen when patients exited from the MARINA or ANCHOR ...a long and arduous process. Emerging terms such as “refractory ... See full document

... Wet age-related macular degeneration (AMD) is the most common reason for vision loss in the United ...and bevacizumab are two examples of anti-VEGF drugs that have been approved; both ... See full document

... mab, bevacizumab, and aflibercept as used in current clinical practice for nAMD will be useful to demonstrate whether the frequency of injection and the long-term costs associated with use of each ... See full document

... Analysis was performed using generalized estimat- ing equations (GEEs) with patients as clusters, logMAR BCVA as the response variable, and CMT and time from initial examination (days) as explanatory variables. Time from ... See full document

... HSCs have attracted much attention as targets for the treatment of liver fibrosis during the last decade. However, anti-fibrotic agents are not taken up efficiently by HSCs because of the closure of endothelial ... See full document

... the treatment group received three fixed monthly treatments and then two sham injections monthly followed by conbercept injection every 3 months until month 12 (IVT con- bercept at months 0, 1, 2, 5, 8, and ...and ... See full document

... to bevacizumab, Kim et al also included other drugs in their study (namely, triamcinolone and ranibizumab) and different needle sizes (27, 30, and 32 gauge), which may explain this ... See full document